142 related articles for article (PubMed ID: 37331189)
21. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
22. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Master VA; Ramalingam SS; Owonikoko TK; Harvey RD
Cancer; 2019 Jan; 125(1):127-134. PubMed ID: 30329148
[TBL] [Abstract][Full Text] [Related]
23. Current concepts in advanced sinonasal mucosal melanoma: a single institution experience.
Meerwein CM; Hüllner M; Braun R; Soyka MB; Morand GB; Holzmann D
Eur Arch Otorhinolaryngol; 2019 Aug; 276(8):2259-2265. PubMed ID: 31098872
[TBL] [Abstract][Full Text] [Related]
24. Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis.
Farrow NE; Turner MC; Salama AKS; Beasley GM
Oncol Ther; 2020 Dec; 8(2):261-275. PubMed ID: 32700043
[TBL] [Abstract][Full Text] [Related]
25. Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.
Kim SH; Kim JK; Park EY; Joo J; Lee KH; Seo HK; Joung JY; Chung J
PLoS One; 2019; 14(2):e0211105. PubMed ID: 30785902
[TBL] [Abstract][Full Text] [Related]
26. Effect of Immunotherapy Status on Outcomes in Patients With Metastatic Melanoma to the Spine.
Shankar GM; Choi BD; Grannan BL; Oh K; Shin JH
Spine (Phila Pa 1976); 2017 Jun; 42(12):E721-E725. PubMed ID: 27879568
[TBL] [Abstract][Full Text] [Related]
27. Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma.
Lehrich BM; Abiri A; Goshtasbi K; Birkenbeuel J; Yasaka TM; Papagiannopoulos P; Tajudeen BA; Brem EA; Kuan EC
Laryngoscope; 2021 Nov; 131(11):E2727-E2735. PubMed ID: 33899946
[TBL] [Abstract][Full Text] [Related]
28. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
29. Surgical Utilization and Outcomes for Patients with Stage IV Melanoma in the Modern Immunotherapy Era.
Lwin TM; Kaelberer Z; Ruan M; Molina G; Boland G
Ann Surg Oncol; 2023 Aug; 30(8):5005-5012. PubMed ID: 37121988
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
31. Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503948
[TBL] [Abstract][Full Text] [Related]
32. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
33. Serum Cell Division Cycle 42 before and after Programmed Death-1 Inhibitor Therapy in Advanced Melanoma Patients: Correlation with Tumor Features, Clinical Response, and Survival.
Zhang L; Zhang S; Han Z; Liu Z; Xu Y; Li X; Miao G; Niu L
Tohoku J Exp Med; 2024 Mar; 262(2):133-141. PubMed ID: 37914283
[TBL] [Abstract][Full Text] [Related]
34. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
35. Prognosis and Management of Thick and Ultrathick Melanoma.
Blakely AM; Cohen JT; Comissiong DS; Vezeridis MP; Miner TJ
Am J Clin Oncol; 2019 Nov; 42(11):824-829. PubMed ID: 31517636
[TBL] [Abstract][Full Text] [Related]
36. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
39. Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
Al-Qurayshi Z; Crowther JE; Hamner JB; Ducoin C; Killackey MT; Kandil E
Anticancer Res; 2018 May; 38(5):2897-2901. PubMed ID: 29715114
[TBL] [Abstract][Full Text] [Related]
40. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study.
Rutkowski P; Indini A; De Luca M; Merelli B; Mariuk-Jarema A; Teterycz P; Rogala P; Lugowska I; Cybulska-Stopa B; Labianca A; Di Guardo L; Del Vecchio M; Pigozzo J; Randon G; Corti F; Tondini CA; Rulli E; Mandala M
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
